We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-2.68%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$17.3B
AUM Growth
-$1.1B
Cap. Flow
-$283M
Cap. Flow %
-1.64%
Top 10 Hldgs %
87.61%
Holding
112
New
6
Increased
21
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$42.9M
2
ROIV icon
Roivant Sciences
ROIV
+$41.6M
3
ABCL icon
AbCellera Biologics
ABCL
+$40.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$20.6M
5
IMGN
Immunogen Inc
IMGN
+$17.9M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$469M
2
KYNB
Kyntra Bio
KYNB
+$39.7M
3
BPMC
Blueprint Medicines
BPMC
+$15M
4
KRYS icon
Krystal Biotech
KRYS
+$13.6M
5
VSTM icon
Verastem
VSTM
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.2%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNLI icon
26
Denali Therapeutics
DNLI
$3.98B
$42.9M 0.25%
1,455,322
+366,584
+34% +$10.3M
KNSA icon
27
Kiniksa Pharmaceuticals
KNSA
$6.17B
$39.6M 0.23%
2,809,577
+10,000
+0.4% +$134K
CERS icon
28
Cerus
CERS
$566M
$39.5M 0.23%
16,067,558
– –
NRIX icon
29
Nurix Therapeutics
NRIX
$2.77B
$38.8M 0.22%
3,882,125
– –
RARE icon
30
Ultragenyx Pharmaceutical
RARE
$2.55B
$36.1M 0.21%
783,059
+312,085
+66% +$14.5M
JBIO
31
Jade Biosciences
JBIO
$1.36B
$33.7M 0.19%
56,099
– –
IGMS
32
DELISTED
IGM Biosciences
IGMS
$29.1M 0.17%
3,157,210
+554
+0% +$6.21K
XENE icon
33
Xenon Pharmaceuticals
XENE
$5.88B
$28.9M 0.17%
751,639
– –
IMGN
34
DELISTED
Immunogen Inc
IMGN
$28.7M 0.17%
+1,520,097
New +$17.9M
DBVT
35
DBV Technologies
DBVT
$914M
$27.8M 0.16%
1,461,426
– –
VERV
36
DELISTED
Verve Therapeutics
VERV
$26.6M 0.15%
1,416,530
– –
TSVT
37
DELISTED
2seventy bio
TSVT
$25.3M 0.15%
2,497,526
– –
IDYA icon
38
IDEAYA Biosciences
IDYA
$3.83B
$25M 0.14%
1,062,123
+229,354
+28% +$4.72M
STOK icon
39
Stoke Therapeutics
STOK
$2.08B
$22.6M 0.13%
2,130,238
+14,822
+0.7% +$158K
BCYC
40
Bicycle Therapeutics
BCYC
$306M
$21.5M 0.12%
843,814
– –
GLUE icon
41
Monte Rosa Therapeutics
GLUE
$1.22B
$20.7M 0.12%
3,023,951
+2,648,856
+706% +$17.1M
CABA icon
42
Cabaletta Bio
CABA
$531M
$20.6M 0.12%
1,594,000
+250,000
+19% +$2.71M
KRYS icon
43
Krystal Biotech
KRYS
$10.3B
$20M 0.12%
169,934
-132,782
-44% -$13.6M
SMMT icon
44
Summit Therapeutics
SMMT
$10.5B
$15.8M 0.09%
6,304,705
– –
ANAB icon
45
AnaptysBio
ANAB
$1.71B
$15.8M 0.09%
775,924
– –
PRME icon
46
Prime Medicine
PRME
$615M
$15.1M 0.09%
1,028,466
– –
PACB icon
47
Pacific Biosciences
PACB
$420M
$15M 0.09%
1,127,782
– –
RLAY icon
48
Relay Therapeutics
RLAY
$4.26B
$14.6M 0.08%
1,160,117
+876,117
+308% +$10.9M
SPRY icon
49
ARS Pharmaceuticals
SPRY
$547M
$13.4M 0.08%
2,006,451
– –
DAWN
50
DELISTED
Day One Biopharmaceuticals
DAWN
$11.9M 0.07%
+1,000,000
New +$13.1M
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2023 Portfolio in Review

As of Q2 2023, Julian Baker held 112 positions worth $17.3B, down 6% from $18.4B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Julian Baker's Q2 2023 filing shows 6 new, 21 increased, 12 reduced and 5 closed positions. Its largest new stake was Immunogen Inc: 1,520,097 shares worth $28.7M. The largest sale was Seagen Inc. Common Stock, an estimated $469M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q2 2023 buy was Immunogen Inc: 1,520,097 shares worth $28.7M.
  • Julian Baker added most to Kymera Therapeutics in Q2 2023, an estimated $42.9M increase.
  • Julian Baker's biggest Q2 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $469M.
  • Julian Baker fully exited Blueprint Medicines in Q2 2023, selling an estimated $15M.
  • Julian Baker's ten largest holdings make up 88% of its $17.3B portfolio in Q2 2023.
  • Julian Baker opened 6 new positions and closed 5 in Q2 2023.
  • Julian Baker's portfolio value fell 6% quarter-over-quarter to $17.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.